BMS 753

RARα-selective agonist CAS# 215307-86-1

BMS 753

Catalog No. BCC6031----Order now to get a substantial discount!

Product Name & Size Price Stock
BMS 753: 5mg $104 In Stock
BMS 753: 10mg Please Inquire In Stock
BMS 753: 20mg Please Inquire Please Inquire
BMS 753: 50mg Please Inquire Please Inquire
BMS 753: 100mg Please Inquire Please Inquire
BMS 753: 200mg Please Inquire Please Inquire
BMS 753: 500mg Please Inquire Please Inquire
BMS 753: 1000mg Please Inquire Please Inquire
Related Products
  • DAPT (GSI-IX)

    Catalog No.:BCC3618
    CAS No.:208255-80-5
  • MK-0752

    Catalog No.:BCC2090
    CAS No.:471905-41-6
  • Flurizan

    Catalog No.:BCC2342
    CAS No.:51543-40-9
  • JLK 6

    Catalog No.:BCC2343
    CAS No.:62252-26-0
  • Begacestat

    Catalog No.:BCC2346
    CAS No.:769169-27-9
  • E 2012

    Catalog No.:BCC1540
    CAS No.:870843-42-8

Quality Control of BMS 753

Number of papers citing our products

Chemical structure

BMS 753

3D structure

Chemical Properties of BMS 753

Cas No. 215307-86-1 SDF Download SDF
PubChem ID 9884820 Appearance Powder
Formula C21H21NO4 M.Wt 351.4
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 100 mM in ethanol
Chemical Name 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid
SMILES CC1(C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C(C1=O)(C)C)C
Standard InChIKey KFBPBWUZXBYJDG-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H21NO4/c1-20(2)15-10-7-13(11-16(15)21(3,4)19(20)26)17(23)22-14-8-5-12(6-9-14)18(24)25/h5-11H,1-4H3,(H,22,23)(H,24,25)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BMS 753

DescriptionRARα-selective agonist (Ki = 2 nM).

BMS 753 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BMS 753 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BMS 753

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8458 mL 14.2288 mL 28.4576 mL 56.9152 mL 71.144 mL
5 mM 0.5692 mL 2.8458 mL 5.6915 mL 11.383 mL 14.2288 mL
10 mM 0.2846 mL 1.4229 mL 2.8458 mL 5.6915 mL 7.1144 mL
50 mM 0.0569 mL 0.2846 mL 0.5692 mL 1.1383 mL 1.4229 mL
100 mM 0.0285 mL 0.1423 mL 0.2846 mL 0.5692 mL 0.7114 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BMS 753

Ki : 2 nM for RARα

Three retinoic acid receptors (RARα, RARβ and RARγ and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids (all-tratis and 9-cis retinoic acids; t-RA and 9c-RA) upon development, cell differentiation and proliferation, and homeostasis. BMS 753 is identified as a RARα-selective agonist.

In vitro: Increasing concentrations of BMS 753 resulted in low levels of RARβ2 transcripts in WT cells, even at the highest concentration, while 100 nM BMS 753 efficiently induced RARβ2 transcripts in RARγ-/- cells. In contrast, no activation was seen in RARα-/- cells up to 100 nM BMS 753, demonstrating that it is specific for RARα [1].

In vivo: To investigate whether similar RARα-dependent events in Sertoli cells (SC) also operate in the reinitiation of spermatogenesis in a vitamin A-deficient (VAD) testis, Rbp4-null adult males fed a VAD diet for 14 wk were treated with BMS 753 or with its vehicle only. Interestingly, spermatogenesis did not initiate upon administration of BMS 753 to VAD Rbp4-null mutants; only SC and spermatogonia were present in their seminiferous epithelium, as in the vehicle-treated situation [2].

Clinical trial: Up to now, BMS 753 is still in the preclinical development stage.

Reference:
[1] RESHMA TANEJA, BIDYUT ROY, JEAN-Luc PLASSAT, CHRIS F.  ZuSIt, JACEK OSTROWSKIS, PETER R. RECZEKS, AND PIERRE CHAMBON. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RARβ2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc. Natl. Acad. Sci. USA Vol. 93, pp. 6197-6202, June 1996.
[2] Raverdeau M, Gely-Pernot A, Féret B, Dennefeld C, Benoit G, Davidson I, Chambon P, Mark M, Ghyselinck NB.  Retinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16582-7.

Featured Products
New Products
 

References on BMS 753

Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists.[Pubmed:10421757]

Chem Biol. 1999 Aug;6(8):519-29.

BACKGROUND: Many synthetic retinoids have been generated that exhibit a distinct pattern of agonist/antagonist activities with the three retinoic acid receptors (RARalpha, RARbeta and RARgamma). Because these retinoids are selective tools with which to dissect the pleiotropic functions of the natural pan-agonist, retinoic acid, and might constitute new therapeutic drugs, we have determined the structural basis of their receptor specificity and compared their activities in animal and yeast cells. RESULTS: There are only three divergent amino acid residues in the ligand binding pockets (LBPs) of RARalpha, RARbeta and RARgamma. We demonstrate here that the ability of monospecific (class I) retinoid agonists and antagonists to bind to and induce or inhibit transactivation by a given isotype is directly linked to the nature of these residues. The agonist/antagonist potential of class II retinoids, which bind to all three RARs but depending on the RAR isotype have the potential to act as agonists or antagonists, was also largely determined by the three divergent LBP residues. These mutational studies were complemented by modelling, on the basis of the three-dimensional structures of the RAR ligand-binding domains, and a comparison of the retinoid agonist/antagonist activities in animal and yeast cells. CONCLUSIONS: Our results reveal the rational basis of RAR isotype selectivity, explain the existence of class I and II retinoids, and provide a structural concept of ligand-mediated antagonism. Interestingly, the agonist/antagonist characteristics of retinoids are not conserved in yeast cells, suggesting that yeast co-regulators interact with RARs in a different way than the animal cell homologues do.

Keywords:

BMS 753,215307-86-1,Natural Products,Retinoic Acid Receptors, buy BMS 753 , BMS 753 supplier , purchase BMS 753 , BMS 753 cost , BMS 753 manufacturer , order BMS 753 , high purity BMS 753

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: